

# Konstantinos P Imprialos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7362101/publications.pdf>

Version: 2024-02-01

88  
papers

1,337  
citations

471061

17  
h-index

395343

33  
g-index

88  
all docs

88  
docs citations

88  
times ranked

1988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Microvascular Complications of Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2020, 18, 117-124.	0.8	235
2	Diabetes and lipid metabolism. <i>Hormones</i> , 2018, 17, 61-67.	0.9	192
3	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2018, 16, 246-253.	0.8	69
4	Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease. <i>Journal of Hypertension</i> , 2015, 33, 2185-2197.	0.3	60
5	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , 2018, 16, 130-142.	0.8	54
6	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 249-253.	0.9	45
7	Hypertension in Metabolic Syndrome: Novel Insights. <i>Current Hypertension Reviews</i> , 2020, 16, 12-18.	0.5	42
8	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2019, 24, 4587-4592.	0.9	42
9	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , 2020, 22, 90.	1.5	35
10	Dysmetabolic Iron Overload in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2020, 26, 1019-1024.	0.9	34
11	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. <i>Journal of Clinical Hypertension</i> , 2020, 22, 572-584.	1.0	29
12	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. <i>Journal of Human Hypertension</i> , 2020, 34, 764-767.	1.0	25
13	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , 2020, 38, 1220-1234.	0.3	25
14	Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. <i>Current Diabetes Reviews</i> , 2020, 16, 313-326.	0.6	24
15	Echocardiographic Parameters During Long and Short Interdialytic Intervals in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2016, 68, 772-781.	2.1	22
16	The Role of Mean Platelet Volume in Chronic Obstructive Pulmonary Disease Exacerbation. <i>Respiratory Care</i> , 2016, 61, 44-49.	0.8	19
17	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , 2018, 12, 29-40.	0.6	19
18	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 331-339.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107927.	1.1	16
20	Is very low LDL-C harmful?. <i>Current Pharmaceutical Design</i> , 2019, 24, 3658-3664.	0.9	16
21	Hematocrit and Stroke: A Forgotten and Neglected Link?. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 591-598.	1.5	15
22	Editorial: Arterial Stiffness, Central Haemodynamics and Non-Alcoholic Fatty Liver Disease: Links with Cardiovascular Risk and Effects of Drug Treatment. <i>Current Vascular Pharmacology</i> , 2018, 16, 401-404.	0.8	15
23	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. <i>Current Pharmaceutical Design</i> , 2017, 23, 1510-1521.	0.9	15
24	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , 2020, 19, 323-342.	0.8	15
25	Recent advances in understanding and managing resistant/refractory hypertension. <i>F1000Research</i> , 2020, 9, 169.	0.8	14
26	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. <i>Current Pharmaceutical Design</i> , 2017, 23, 1540-1550.	0.9	14
27	Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome. <i>Gynecological Endocrinology</i> , 2024, 34, 1019-1021.	0.7	13
28	Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2018, 16, 239-245.	0.8	13
29	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. <i>Current Clinical Pharmacology</i> , 2019, 13, 261-272.	0.2	13
30	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 942-948.	1.0	10
31	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1251-1261.	1.3	9
32	Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 65-68.	1.0	9
33	Treatment strategies for hypertension in patients with type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1241-1252.	0.9	9
34	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020, 18, 125-138.	0.8	9
35	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 241-251.	1.0	8
36	Primary Aldosteronism: Novel Insights. <i>Current Hypertension Reviews</i> , 2020, 16, 19-23.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , 2020, 19, 301-312.	0.8	8
38	Female Sexual Dysfunction: A Problem Hidden in the Shadows. <i>Current Pharmaceutical Design</i> , 2021, 27, 3762-3774.	0.9	7
39	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. <i>Current Pharmaceutical Design</i> , 2019, 24, 5517-5524.	0.9	7
40	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. <i>American Journal of Hypertension</i> , 2016, 29, 662-662.	1.0	6
41	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. <i>Journal of Clinical Hypertension</i> , 2017, 19, 798-800.	1.0	6
42	Introducing In Vivo Dissection Modules for Undergraduate Level Trainees: What Is the Actual Benefit and How Could We Make It More Efficient?. <i>Indian Journal of Surgery</i> , 2018, 80, 68-76.	0.2	6
43	Pharmacological Management of Type 2 Diabetes Complications. <i>Current Vascular Pharmacology</i> , 2020, 18, 101-103.	0.8	6
44	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 120-126.	0.2	5
45	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. <i>Journal of Sexual Medicine</i> , 2019, 16, 1199-1211.	0.3	5
46	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. <i>European Journal of Internal Medicine</i> , 2020, 77, 153-155.	1.0	5
47	Carotid intima-media thickness as a target organ damage and treatment target: Need for a major revision?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 255-257.	1.0	4
48	Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension. <i>Current Pharmaceutical Design</i> , 2019, 24, 5500-5507.	0.9	4
49	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , 2018, 16, 276-288.	0.8	4
50	Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 94-103.	0.2	4
51	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. <i>Journal of Human Hypertension</i> , 2022, 36, 1066-1071.	1.0	4
52	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1073-1073.	1.0	3
53	Abnormal blood pressure dipping in diabetic kidney disease: A black face nightmare?. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1336-1338.	1.0	3
54	Insomnia and hypertension: A misty landscape. <i>Journal of Clinical Hypertension</i> , 2019, 21, 835-837.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2020, 125, 887-893.	0.7	3
56	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. <i>Clinical Lipidology</i> , 2016, 11, 2-5.	0.4	3
57	Testosterone Replacement Therapy and Cardiovascular Risk—A Closer Look at Additional Parameters. <i>JAMA Internal Medicine</i> , 2017, 177, 1393.	2.6	2
58	Subclinical target organ damage in primary aldosteronism. <i>Journal of Hypertension</i> , 2018, 36, 701.	0.3	2
59	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 634-636.	1.0	2
60	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 469-471.	1.0	2
61	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 519-530.	1.0	2
62	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1578-1579.	1.0	2
63	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. <i>American Journal of Cardiology</i> , 2020, 137, 133-135.	0.7	2
64	Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. <i>International Journal of Cardiology</i> , 2020, 316, 240-241.	0.8	2
65	Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia. <i>Current Vascular Pharmacology</i> , 2021, 19, 449-450.	0.8	2
66	Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 104-113.	0.2	2
67	Impact of Primary Aldosteronism in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2022, , 1.	1.5	2
68	Renin—Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 828-828.	1.0	1
69	Depression in hypertensive patients. <i>Journal of Hypertension</i> , 2016, 34, 1441.	0.3	1
70	Blood pressure and cardiovascular outcomes: a closer look. <i>Lancet</i> , The, 2017, 389, 1295-1296.	6.3	1
71	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. <i>Journal of Clinical Hypertension</i> , 2018, 20, 589-591.	1.0	1
72	What is the role of statins in the elderly population?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 329-331.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Antihypertensive drug treatment: the real-life challenge. <i>Journal of Clinical Hypertension</i> , 2018, 20, 115-117.	1.0	1
74	Letter by Stavropoulos et al Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control." <i>Circulation</i> , 2018, 137, 2664-2665.	1.6	1
75	Determinants of pulse wave velocity index and potential implementations. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1493-1495.	1.0	1
76	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. <i>American Journal of Cardiology</i> , 2021, 138, 116-118.	0.7	1
77	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. <i>Kardiologia Polska</i> , 2022, 80, 696-698.	0.3	1
78	Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation." <i>Circulation</i> , 2016, 134, e5-6.	1.6	0
79	PATHWAY-2: spironolactone for resistant hypertension. <i>Lancet, The</i> , 2016, 387, 1371-1372.	6.3	0
80	Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function. <i>JAMA Internal Medicine</i> , 2016, 176, 409.	2.6	0
81	Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 83-85.	0.2	0
82	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 3597-3598.	0.9	0
83	Coronary angiography and acute kidney injury: The dawn for novel markers. <i>International Journal of Cardiology</i> , 2020, 304, 175-176.	0.8	0
84	Coronary angiography and acute kidney injury: The dawn for novel markers. <i>International Journal of Cardiology</i> , 2020, 300, 119-120.	0.8	0
85	The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. <i>Angiology</i> , 2022, 73, 000331972110055.	0.8	0
86	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 331-332.	4.5	0
87	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 648-650.	0.3	0
88	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. <i>Kardiologia Polska</i> , 2022, 80, 80-82.	0.3	0